Please login to the form below

Not currently logged in
Email:
Password:

Ex GSK exec to lead Sanford-Burnham

Perry Nisen appointed CEO at research institute
sanford-Burnham perry nisen

Dr Perry Nisen has left his senior role at GlaxoSmithKline (GSK) to become CEO of Sanford-Burnham Medical Research Institute in California.

Dr Nisen was senior VP, science and innovation at GSK. Based in Pennsylvania he provided scientific and medical leadership, counsel, and governance to GSK at a global level.

He now heads up one of the world's most prestigious research organisations as it commences its 10-year strategic vision to more quickly translate basic research discoveries into novel treatments that improve human health.

Dr Nisen's experience at a pharma company will be crucial as Sanford-Burnham looks to “expand its efforts to cross the traditional boundary between academic research and commercialisation,” said Gregory Lucier, chairman of Sanford-Burnham's board of trustees.

Sanford-Burnham is looking to capitalise on pharma's changing research model as companies downsize and outsource early-stage discovery and take a more open innovation approach.

"Sanford-Burnham's agile structure, no-barriers science, and partnership approach are key drivers of innovation and are extremely attractive to me,” said Dr Nisen.

The Institute has been led by Dr Kristiina Vuori on an interim basis since the departure of former CEO John Reed in early 2013. In contrast to Dr Perry Nisen, Dr Reed left Sanford-Burnham to join the pharma industry as head of research and early development at Roche.

Dr Vuori commented on her successor: “Given Dr Nisen's extensive experience in target-to-market development of medicines, he is exceptionally well suited to lead the Institute and the implementation of our strategic vision.”

22nd August 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics